A cluster of FDA clearances over the past year has turned ordinary wrist- and finger-worn wearables into tools that can flag one of the most underdiagnosed conditions in American medicine: obstructive sleep apnea. Samsung secured FDA clearance for AI-powered sleep apnea detection on its smartwatches in February 2025, and Apple followed in September 2025, putting the capability in front of millions of existing device owners. On top of the major consumer brands, smaller medical-device makers pushed further into clinical-grade territory, and on January 6, 2026, the FDA issued new guidance documents reshaping how it will treat this entire category going forward.
From Wellness Gadget to Diagnostic Aid
Sleep apnea affects an estimated tens of millions of adults in the United States, and the American Academy of Sleep Medicine has long noted that most cases go undiagnosed because the gold-standard test, an overnight polysomnography sleep study, requires a lab visit, specialized equipment, and often a long wait for a clinic appointment. That bottleneck is what device makers have targeted with AI-enabled home sleep apnea tests, or HSATs, that analyze breathing, oxygen, and movement patterns using biosensors and machine learning rather than a technician-monitored lab bed.
The New Wave of Clearances
PranaQ announced in February 2025 that it received FDA 510(k) clearance for TipTraQ, a compact home sleep apnea test that uses AI algorithms to detect sleep apnea events and analyze sleep architecture with what the company describes as clinical-grade accuracy, according to the American Academy of Sleep Medicine. Happy Health’s Happy Ring, a smart ring competitor to Oura, gained its own FDA clearance in June 2025. Combined with Samsung’s and Apple’s smartwatch clearances, the result is a rapidly expanding menu of consumer-accessible devices that can flag apnea risk without a lab referral.
The FDA Rewrites the Rules
On January 6, 2026, the FDA issued updated guidance on General Wellness: Policy for Low-Risk Devices and on Clinical Decision Support Software, according to law firm analyses from Ropes & Gray, Covington & Burling, and Faegre Drinker. The revised framework draws a sharper line between wellness claims, such as informing users about sleep, activity, or stress, which require minimal regulatory oversight, and medical or clinical claims, such as screening, diagnosing, or managing a disease, which still require full review. Under the new guidance, a wrist-worn wearable that tracks sleep, pulse rate, and blood pressure can qualify for general wellness status as long as its values are properly validated and it avoids diagnostic language.
The timing was notable: the guidance update came roughly four months after the FDA issued a warning letter to WHOOP in 2025 over how the company marketed physiological metrics like blood pressure estimates, according to reporting from MedTech Dive and Healthcare Dive. Regulators appear to be trying to give manufacturers clearer rules of the road rather than adjudicating each borderline health claim case by case.
Two Views on Loosening the Reins
Medtech companies and some digital health investors have welcomed the clarified guidance, arguing that it removes years of ambiguity that discouraged innovation in low-risk wellness features and lets companies iterate faster on sleep, stress, and activity tools that never claimed to replace a doctor. Industry attorneys quoted in coverage from McDermott Will & Emery described the shift as the FDA "clearing the runway" for wearables and AI.
Sleep physicians are more circumspect. Clinicians who work with polysomnography note that consumer AI tools, even FDA-cleared ones, are validated against specific patient populations and use cases, and that a positive apnea flag from a smartwatch should prompt a conversation with a doctor rather than a self-diagnosis. There is also a structural worry: as more borderline metrics get folded into the "general wellness" bucket to avoid the stricter clinical pathway, the line between a wellness insight and a de facto diagnosis could blur for the average consumer, even if the label technically avoids the word "diagnose."
What It Means for a Crowded Wearables Market
For consumers, the practical effect is that more devices at more price points will likely advertise sleep apnea risk detection over the next year, intensifying competition between Apple, Samsung, Oura, Whoop, and specialized medical-device entrants like PranaQ. For the health system, the open question is whether all this new data actually gets people into treatment faster, or simply generates more anxious patients clutching wearable alerts with nowhere efficient to take them. The FDA’s January 2026 guidance suggests regulators are betting that clearer rules, rather than tighter restrictions, will let the market sort that out, while reserving stricter review for any device that crosses from wellness insight into diagnostic claim.
